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Abstract
Background: The myeloid translocation gene (MTG) proteins are non-DNA-binding
transcriptional regulators capable of interacting with chromatin modifying proteins. As a
consequence of leukemia-associated chromosomal translocations, two of the MTG proteins,
MTG8 and MTG16, are fused to the DNA-binding domain of AML1, a transcriptional activator
crucial for hematopoiesis. The AML1-MTG fusion proteins, as the wild type MTGs, display four
conserved homology regions (NHR1-4) related to the Drosophila nervy protein. Structural protein
analyses led us to test the hypothesis that specific MTG domains may mediate RNA binding.
Results: By using an RNA-binding assay based on synthetic RNA homopolymers and a panel of
MTG deletion mutants, here we show that all the MTG proteins can bind RNA. The RNA-binding
properties can be traced to two regions: the Zinc finger domains in the NHR4, which mediate Zinc-
dependent RNA binding, and a novel short basic region (SBR) upstream of the NHR2, which
mediates Zinc-independent RNA binding. The two AML1-MTG fusion proteins, retaining both the
Zinc fingers domains and the SBR, also display RNA-binding properties.
Conclusion: Evidence has been accumulating that RNA plays a role in transcriptional control. Both
wild type MTGs and chimeric AML1-MTG proteins display in vitro RNA-binding properties, thus
opening new perspectives on the possible involvement of an RNA component in MTG-mediated
chromatin regulation.
Background
The myeloid translocation gene (MTG) protein family
includes three human members: MTG8 (ETO/CBFA2T1)
[1-3], MTGR1 (CBFA2T2) [4-6] and MTG16 (CBFA2T3)
[7]. The MTG proteins share four conserved domains that
can be traced to the Drosophila protein nervy, and there-
fore called nervy homology regions (NHR1-4) [6]. These
domains carry information for distinct, but integrated,
functional properties. The NHR1 domain can positively
or negatively modulate transcription through interaction
with either co-repressors or transcriptional activators [8].
The NHR2 domain is required for interaction with other
MTG proteins and with the transcriptional co-repressor
Sin3A [6,9-11]. The NHR4 domain, even if it contains two
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[12,13]; instead, it binds both co-repressor proteins,
including N-CoR/SMRT, and histone deacetylases
(HDACs) [11,14,15]. We and others showed that the
MTG proteins can act as chromatin repressors due to their
ability to recruit HDAC activity, either directly
[10,11,16,17] or via the co-repressors N-CoR/SMRT and
Sin3A [14,15,18]. Further, it has been demonstrated that
both MTG8 and MTG16 can induce transcriptional repres-
sion of reporter genes [10,15,17,19]. Since the MTG pro-
teins do not bind to DNA directly, their transcriptional
repressive action is dependent on the binding to transcrip-
tion factors able to recognize specific target-genes ([20]
and references within).
As a consequence of the leukemia-associated chromo-
somal translocations t(8;21) and t(16;21), MTG8 and
MTG16 are fused to AML1 (RUNX1), a transcription fac-
tor crucial for hematopoiesis. The resulting fusion pro-
teins AML1-MTG8 (AML1-ETO) and AML1-MTG16 retain
the DNA-binding domain of AML1 (Runt Homology
Domain, RHD) and all the four functional NHR domains
of the MTG proteins (for detailed reviews see [12,21-24]).
Both AML1-MTG8 and AML1-MTG16 can bind to AML1-
target genes, recruit HDAC activity, and induce a repressed
chromatin state [20,25-27]. In vitro studies suggest that
epigenetic downregulation/silencing of these target genes
may be a key step in leukemogenesis [12,21-24].
More and more evidence has been accumulating that
RNA, in particular non-coding RNA (ncRNA), can play an
important role in the epigenetic control of chromatin [28-
30]. The MTG proteins are transcriptional regulators
equipped with non-DNA-binding ZF domains, which
have been described to mediate protein-RNA interactions
in other proteins [31]. Based on this observation, we pre-
viously hypothesized that transcriptional regulation by
the MTG proteins might involve an RNA component [20].
To start to address this hypothesis, we set out to investi-
gate whether the MTG proteins have RNA-binding proper-
ties. By using a well established RNA-binding assay based
on synthetic RNA homopolymers [32], here we show that
indeed this is the case. Two regions mediate the RNA
binding: the zinc-finger domains in the NHR4 region and
a novel RNA-binding short basic region (SBR) proximal to
the NHR2 region. We further show that the two oncogenic
fusion proteins AML1-MTG8 and AML1-MTG16, retain-
ing these two regions, maintain also RNA-binding proper-
ties.
Results
The MTG proteins have RNA-binding properties
We investigated the RNA-binding properties of MTG8,
MTG16 and MTGR1 by analyzing their ability to interact
with four synthetic RNA homopolymers, poly(A),
poly(C), poly(G) and poly(U), coupled to Sepharose
beads. This method has been previously proven to be suit-
able for studying RNA-binding properties of RNA-binding
proteins, including the Fragile × mental retardation pro-
tein FMRP, which we used in this study as a positive con-
trol [33-35]. The three MTGs, exogenously expressed in
COS cells, display binding to both poly(U) and poly(G),
but no binding to poly(A) and poly(C), thus showing the
same properties of the control RNA-binding protein
FMRP (Figure 1A). All MTGs did not bind uncoupled
Sepharose beads, indicating specific affinity for RNA (Fig-
ure 1A). For the remainder of this study we chose to use
only poly(U) RNA. Digestion with micrococcal nuclease
of the Sepharose-conjugated poly(U) homopolymer
apparently abolishes MTGs precipitation (here shown for
MTG16), demonstrating that the binding occurs via
poly(U) RNA (Figure 1B). In addition, we showed that
known non-RNA-binding proteins, such as BSA and GFP,
were not able to bind poly(U) RNA under the experimen-
tal conditions used (Figure 1B). These indicate that the
RNA-binding properties of the MTG proteins are specific.
Next, we determined the strength of MTGs binding to
poly(U) beads in the presence of 150, 250, 500 and 1000
mM NaCl. All MTGs bound the poly(U) homopolymer at
the physiological salt concentration of 150 mM (Figure
1C). The binding was stable up to 250 mM NaCl, while it
weakened at higher salt concentrations (Figure 1C), which
is not uncommon for other RNA-binding proteins
[36,37]. The RNA-binding strength of the MTG proteins is
similar to the one reported for RNA-binding proteins that,
like the MTGs [20], have multiple functions [38].
Finally, we investigated the influence of posttranslational
modifications of the MTG proteins on the RNA binding.
MTG proteins produced in an in vitro transcription/trans-
lation system, in which posttranslational modifications
do not occur, retained the ability to interact with poly(U)
RNA (Figure 1D). This indicates that posttranslational
modifications are not directly necessary for the observed
RNA binding.
Deletion of the Zinc-finger domains is not sufficient to 
abolish RNA-binding properties
The NHR4, a region conserved across all the MTGs, con-
tains two Zinc Finger (ZF) domains [6]. ZF domains are
known to have DNA-binding properties, but they have
been described to mediate also interaction with RNA [31].
In silico analysis of the MTG8 NHR4 structure indeed sug-
gests that this region is a putative RNA-binding domain.
First, we analyzed the primary structure of the NHR4
region by using the BindN program [39]. This analysis
predicted several RNA-binding residues between ami-
noacid 516 and 542 (Figure 2A, left). Further, we analyzed
the MTG8 NHR4 solution structure, previously solved byPage 2 of 9
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deposited in the Protein Data Bank (PDB), by using Patch
Finder Plus [41,42]. The Patch Finder Plus algorithm
extracts from the three-dimensional (3D) protein struc-
ture positively charged electrostatic patches, which are
known to mediate protein-nucleic-acid interactions. The
algorithm predicted on the surface of the NHR4 domain a
large positive patch (Figure 2A, right), whose amino acid
residues partially overlap with the RNA-binding residues
predicted by the analysis of the NHR4 primary structure
(Figure 2A, left). Because the MTG proteins do not have
DNA-binding properties [13], it is conceivable to hypoth-
esize that this positive patch mediates protein-RNA bind-
ing. For this reason, we further tested the predicted RNA-
binding in vitro, by developing two MTG8 deletion
mutants either lacking the ZF-containing C-terminus
(MTG8Δ1) or the N-terminus (MTG8Δ2) (Figure 2B, left).
The MTG8 epitope recognized by our AB-8 antibody [16]
(Figure 2B, left) allowed the detection of these deletion
mutants without using protein tags, which might interfere
with the RNA-binding. Deletion of the MTG8 C-terminus
(MTG8Δ1) did not affect the binding to poly(U) (Figure
2B, right), thus indicating that RNA-binding domains
other than the ZF might be present. This supposition is
further supported by the observation that both MTG8 and
MTG8Δ1 bind to poly(U) even in the absence of ZnCl2
(Figure 2B, right), which would be necessary for a ZF-
mediated interaction. Since deletion of MTG8 N-terminus
The MTG proteins have RNA-binding propertiesFigure 1
The MTG proteins have RNA-binding properties. A. RNA-binding assay using Sepharose-conjugated RNA homopoly-
mers followed by Western Blotting shows that MTG8, MTG16 and MTGR1 exogenously expressed in COS cells bind to 
poly(G) and poly(U), while do not bind to poly(A), poly(C) and uncoupled Sepharose beads. FMRP, which we used as a positive 
control, shows similar RNA-binding properties. B. Binding specificity is shown both by the MTG inability to bind poly(U) after 
digestion with micrococcal nuclease (shown here for MTG16), and by the inability to bind poly(U) of two non-RNA-binding 
proteins, BSA (10 μg) and GFP (transiently expressed in COS cells). C. Poly(U)-binding at different concentrations of NaCl 
shows the strength of RNA interaction of the MTG proteins and the control RNA-binding protein FMRP. D) In vitro tran-
scribed and translated (TnT) MTG proteins maintain the ability to bind poly(U).Page 3 of 9
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poly(U) (Figure 2B, right), we hypothesized the presence
of an additional RNA-binding domain common to the
two deletion mutants, in the region encompassing a.a.
305–447.
Identification of a Zinc-independent RNA-binding domain 
proximal to the NHR2 region
To search for potential RNA-binding domains other than
the NHR4 in the MTG8 protein, we used, in addition to
BindN, a second software, RNAbindR. RNAbindR is a
computational tool able to predict RNA-binding amino
acids from a protein primary sequence, based on interac-
tions from structures of known protein-RNA complexes
[43]. Both programs predicted an MTG8 region rich in
RNA-binding residues between a.a. 310 and a.a. 333 (Fig-
ure 3A, top). Analysis of the MTG8 sequence from other
species and other human MTG proteins identified a con-
served short basic region (which we named SBR) within
a.a. 309 and a.a. 328 (Figure 3A, bottom). This region has
a high content in basic amino acids, which are often
involved in nucleic acid binding [44]. Specifically, the
arginines at position 312, 321, 324 and 326 and other
basic residues at position 317 and 358 are conserved from
Xenopus to Human (Figure 3A, bottom). Since the three-
dimensional structure of the SBR is not known, we could
not test for the presence of positively charged protein
patches. However, we established the RNA-binding prop-
erties of the SBR in vitro. By deleting the SBR from
MTG8Δ1, we obtained the deletion mutant MTG8Δ3,
Deletion of the Zinc finger domain in the NHR4 region is not sufficient to abolish RNA bindingFigure 2
Deletion of the Zinc finger domains in the NHR4 region is not sufficient to abolish RNA binding. A. In silico anal-
ysis of the MTG8 NHR4 domain primary structure (left) and solution structure (right), performed by using BindN and Path 
Finder Plus, respectively, identifies putative RNA-binding residues (left). B. Scheme of the MTG8 deletion mutants showing 
MTGs conserved domains (NHRs), the zinc finger (ZF) domains and the epitope recognized by the anti-MTG8 antibody (AB-8) 
(left). Poly(U)-binding assay performed in the presence or the absence of ZnCl2 (50 μM) shows that neither deletion of MTG8 
C-terminus (MTG8Δ1), containing the ZF domains, nor deletion of the N-terminus (MTG8Δ2) are sufficient to abrogate the 
binding (right).Page 4 of 9
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Identification of SBR, a novel RNA-binding domains proximal to NHR2Figure 3
Identification of SBR, a novel RNA-binding domains proximal to NHR2. A. In silico analysis of the MTG8 protein 
sequence with BindN and RNAbindR software predicts RNA-binding residues in a region between a.a. 316 and a.a. 333 (top). 
This sequence is part of a short basic region (SBR) highly conserved across the three human MTGs and across different species 
(bottom). B. Deletion of MTG8 N-terminus, containing the SBR (MTG8Δ3), abrogates Zinc-independent poly(U)-binding; fur-
ther deletion of MTG8 C-terminus, containing the Zinc Finger (ZF) domains (MTG8Δ4), abrogates also Zinc-dependent 
poly(U)-binding.
BMC Molecular Biology 2008, 9:93 http://www.biomedcentral.com/1471-2199/9/93which lacks a.a. 1–329, but retains the ZF domains in the
C-terminus (Figure 3B, left). MTG8Δ3 was able to bind
poly(U) only in the presence of ZnCl2 (Figure 3B, right),
indicating that the SBR is responsible for the Zinc-inde-
pendent binding to RNA. Another deletion mutant,
MTG8Δ4, missing both the zinc-finger domain and the N-
terminal part, including the SBR, did not bind to poly(U)
either in the presence or in the absence of ZnCl2 (Figure
3B, right), indicating that the ZF domains mediate the
Zinc-dependent RNA-binding. In conclusion, two regions
mediate MTG8 RNA-binding: the canonical ZF domains
in the NHR4 region and a novel Zinc-independent RNA-
binding domain corresponding to the SBR region.
The fusion proteins AML1-MTG8 and AML1-MTG16 
retain the RNA-binding properties of wild type MTGs
As a consequence of the leukemia-associated chromo-
some translocations t(8;21) and t(16;21), almost the
entire MTG8 and MTG16 protein moieties are fused to the
RHD domain of AML1, leading to the chimeric AML1-
MTG8 and AML1-MTG16 proteins, respectively [1-3].
These chimeric proteins retain the AML1 DNA-binding
domain and all the MTGs functional domains, including
the ZF and the SBR RNA-binding domains (Figure 4A).
Here we show that both fusion proteins bind to poly(U)
both in the presence and the absence of ZnCl2 (Figure 4B),
thus indicating that the RNA-binding properties of the
wild type MTG proteins are maintained in their chimeric
counterparts.
Discussion
The MTG proteins are transcriptional regulators capable
of networking with their own family protein members
and a variety of transcriptional regulatory proteins. Appar-
ently, the major MTGs' action relies on the ability of these
adaptor proteins to establish multiple interactions, on
one hand with canonical DNA-binding transcription fac-
tors and, on the other hand, with chromatin regulatory
proteins, including repressor proteins and histone modi-
fying enzymes (reviewed in [20]). The MTGs carry out dis-
tinct, but integrated, functional interactions through
conserved domains, the NHR1-4, homologous to the Dro-
sophila protein Nervy. Despite the presence of two zinc fin-
ger (ZF) motifs in one of the domains (NHR4), the MTG
proteins do not exert their transcriptional regulatory func-
tion by direct DNA binding [12,13].
Based on the observation that ZF motifs can mediate not
only DNA-protein interactions, but also RNA-protein
interactions [44], we previously hypothesized that the ZF-
containing NHR4 domain could confer RNA-binding
properties to both wild type and chimeric MTG proteins
[20]. In this study, by using an in vitro assay based on RNA
homopolymers binding [32], we show that the MTG pro-
teins specifically bind to RNA. We unequivocally demon-
strate the binding specificity by performing a series of
experiments. First, we showed that non-RNA-binding pro-
teins cannot be precipitated by RNA hompolymers under
the same conditions used for the MTGs. Second, digestion
of the poly(U) RNA homopolymer completely abolished
the MTGs binding. Finally, the MTG-RNA interaction was
AML1-MTGs fusion proteins maintain MTGs RNA-binding propertiesFigure 4
AML1-MTGs fusion proteins maintain MTGs RNA-binding properties. A. Both the ZF domains and the SBR region 
are present in AML1-MTG8 and AML1-MTG16. B. AML1-MTG8 and AML1-MTG16 are able to bind poly(U) both in the pres-
ence and the absence of ZnCl2.Page 6 of 9
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bining in silico protein analyses and development of MTG
deletion mutants, we found that the RNA binding is not
only mediated by the ZF domains in the NHR4 region, but
entails also a novel, Zinc-independent, RNA-binding
region proximal to NHR2, the SBR region. The SBR
domain seems to be highly conserved across the three
human MTGs and the MTGs of different species, and it is
rich in basic amino acid residues, a feature frequently
observed in RNA binding domains [44]. To our knowl-
edge, this region is a bona fide novel RNA binding domain,
whose primary and secondary structures do not resemble
canonical RNA-binding domains [44].
The aberrant AML1-MTG fusion proteins retain the ability
of interplaying with both repressor proteins and/or his-
tone modifying enzymes, and can induce an altered epige-
netic status at the chromatin of both coding and non-
coding AML1-target genes [26,27,45]. Apparently, the
fusion of two MTGs, MTG8 and MTG16, to the RHD
region of AML1 does not affect the in vitro RNA-binding
properties.
Whether the wild type and chimeric MTG proteins bind
RNA in vivo remains to be established. The MTG proteins,
like the well-known RNA-binding protein FMRP [33],
bind preferentially to poly(U) and poly(G). This might
suggest a potential affinity for RNAs rich in U and/or G,
such as mRNAs containing short tandem repeats (STR)
made of GU dinucleotides [46] or long poly(U) stretches
([32] and references within) in their 3'untranslated region
(UTR). Further, based on the strength of RNA binding, the
MTG proteins might mediate transient protein-RNA inter-
actions. It is noteworthy that transient RNA-protein inter-
actions often characterize multifunctional proteins, such
as chaperone proteins, with RNA-binding strengths simi-
lar to the ones displayed by the MTGs [38].
Interestingly, the two domains that we found to be
involved in RNA binding in either a Zinc-dependent or a
Zinc-independent fashion are also capable of interacting
with specific chromatin regulatory proteins. Specifically,
the ZF-containing NHR4 domain is known to interact
with both the N-CoR/SMRT proteins and HDACs
[10,11,14,15,18], while the SBR domain is overlapping
with a region (aa. 300–343) involved in HDAC3 binding
[11]. Whether an RNA component initiates, or contrib-
utes, to the assembly of MTGs-containing repressor com-
plexes at specific target sites in the genome remains to be
established. A growing number of RNAs, including non-
coding RNAs, appears to be implicated in chromatin
architecture and chromatin-mediated transcriptional reg-
ulation [28-30]. Due to the already known networking
ability of the MTG proteins [20], it is possible that these
family of proteins are even more versatile than originally
expected, being capable of networking regulatory RNA in
addition to chromatin regulatory/remodelling complexes
at specific sites of the genome.
Conclusion
Evidence has been accumulating that RNA plays a role in
transcriptional control. Both wild type MTGs and leuke-
mia-associated AML1-MTG fusion proteins display novel
in vitro RNA-binding properties. These findings lend sup-
port to the hypothesis of the involvement of an RNA com-
ponent in MTG-mediated chromatin regulation.
Methods
In silico analyses
Prediction of RNA-binding residues in the primary struc-
ture of the MTG8b protein (Acc. # NP_783552) was per-
formed by using the both the BindN [39] and the
RNABindR [43] software. Prediction of the positively
charged, nucleid-acid-binding patches of the MTG8
NHR4 solution structure (PDB ID # 2OD1) was per-
formed by using Patch Finder Plus [41,42]. The SBR
region was further analyzed by multiple alignments with
both the MTG8 proteins of different species (mouse
MTG8, Acc. # NP_001104497; Chicken MTG8, Acc. #
NP_990075, Xenopus MTG8, Acc. # NP_001089065) and
the other human MTG proteins (MTG16a, Acc. #
NP_005178; MTGR1b, Acc # NP_005084). Multiple
alignments were obtained by using the DNAman software
followed by minor manual adjustments.
Cell cultures and transfections
COS-7 were cultured in Dulbecco's modified Eagle's
medium (DMEM) supplemented with 10% fetal calf
serum (FCS) and 1% antibiotics (penicillin and strepto-
mycin) at 37°C and 5% CO2. Cells were transiently trans-
fected with 1 μg of plasmid DNA and Lipofectamine Plus
(Invitrogen, Carlsbad, CA) according to the manufac-
turer's instructions and harvested after 48 h.
Constructs
The psf2 construct containing FMR1 cDNA was previously
described [47]. The cDNAs of wild type MTGs, AML1-
MTGs and MTG8 deletion mutants were subcloned by
PCR into the CMV-driven mammalian expression vector
pcDNA3.1/V5-His TOPO (Invitrogen) leaving or intro-
ducing a stop-codon before the V5-His tag. MTG16a
cDNA was kindly provided by Drs Kosoda and Ohki
(National Cancer Research Institute, Tokyo, Japan) and
amplified with primers P44 (5'-ACC ATG CCG GCT TCA
AGA CT-3') and P10 (5'-CAG GGG CCA GTG GGG TCA-
3'). MTGR1a cDNA was kindly provided by Dr I. Kitaba-
yashi (National Cancer Research Institute, Tokyo, Japan)
and amplified with primers P12 (5'-AAC CAT GCC TGG
ATC GCC TG-3') and P13 (5'-AGC AGA GTC CGG GGC
TCA G-3'). The cDNA of wild type MTG8b was amplifiedPage 7 of 9
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ATA TCT GTC AAA AGA AAC-3') and P7 (5'-TCA CGT CTA
GCG AGG GGT TG-3'). The MTG8 deletion mutants were
amplified from MTG8b cDNA with the following primers:
MTG8Δ1, lacking the region coding for amino acids 449–
604, with primers P122 and P123 (5'-CTC CTC AGC TTA
CTT CCA GAT C-3'); MTG8Δ2, lacking the region coding
for amino acids 1–304, with primers P125 (5'-ACC ATG
GCC ATT GCC CAC CAC TAC-3') and P7; MTG8Δ3, lack-
ing the region coding for amino acids 1–329, with primers
P157 (5'-GTT ATG GGG TTG CAT GGC ACA CG-3') and
P7; MTG8Δ4, lacking the region coding for amino acids
1–329 and 514–604, with primers P157 and P124 (5'-
CCA GCA ACT CTA GCT TGA ATC C-3'). The cDNAs of
AML1-MTG8 and AML1-MTG16 type1 were kindly pro-
vided by Dr I. Kitabayashi and amplified with primers P51
(5'-ACC ATG CGT ATC CCC GTA GAT G-3') and P7, and
P51–P10, respectively.
In vitro transcription translation
In vitro transcription/translation was performed with TnT
Quick Coupled Transcription/Translation System
(Promega, Madison, WI) according to the manufacturer's
instructions. 1 μg of plasmid DNA containing a T7 pro-
moter was used in each reaction. The samples were
directly used for the RNA-binding assay.
RNA-binding assay
The RNA-binding assay was based on the affinity for dif-
ferent RNA homopolymers, as previously described [32].
Approximately 106 transfected cells were homogenized in
binding buffer (10 mM Tris-HCl pH 7.5, 2.5 mM MgCl2,
0.5% Triton X100) containing NaCl in the indicated con-
centrations (150 mM when not mentioned otherwise)
and 50 μM ZnCl2 when not otherwise indicated. The sam-
ples were sonicated 2–3 times for 15 sec. and spun down
for 5' at 13000 rpm at 4°C. A small part of the homoge-
nate was saved as total sample and the rest was split and
used for binding to 60 μl of Sepharose 4B-poly(U), -
poly(A) (both from GE Healthcare, Piscataway, NJ), -poly
(C) or -poly(G) (both from Sigma) beads previously
washed and diluted 1:1 in binding buffer. As a negative
control we either used beads treated with 50 U/ml micro-
coccal nuclease for 1 h 30°C or ECH Sepharose 4B (GE
Healthcare). After incubation at 4°C for 1 h on a rocking
platform, the beads were washed 5 times with 1 ml bind-
ing buffer and finally eluted with NuPage LDS Sample
Buffer (Invitrogen). Samples were analyzed on SDS-PAGE
followed by Western blotting. Immunodetection was per-
formed with antibodies that we developed against MTG8
(AB-8, rabbit polyclonal, 1:2000), MTG16 (AB-16, rabbit
polyclonal, 1:2000), MTGR1 (AB-R1, rabbit polyclonal,
1:2000) [16], and FMRP (1A, mouse monoclonal,
1:4000) [35]. Commercial antibodies were used for BSA
(Sigma, mouse monoclonal, 1:1000) and GFP (Roche,
mouse monoclonal, 1:1000). Incubation with the pri-
mary antibody was followed by incubation with HRP-
conjugated anti-rabbit and anti-mouse secondary anti-
bodies (GE Healthcare, 1:5000) and ECL detection (GE
Healthcare).
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